Recent developments include securing multi-million-dollar contracts, entering the breast cancer marketplace, advancing product development, and strengthening the balance sheet through equity raises and asset sales.

• Odyssey Health secured a multi-million-dollar, nine-year service contract and financing facility for up to $25 million.[N1]
• The company entered the $26 billion breast cancer marketplace as of October 2025.[N1]
• Odyssey Health advanced development of its Save A Life choking rescue device.[N1]
• The company closed an asset sale of its neurological drug technology pipeline including a concussion drug candidate with Oragenics, Inc.[N1]
• Odyssey Health strengthened its balance sheet with $8.7 million in net equity as of March 2024.[N1]
• The company has been active in investor relations and business development activities, including agreements with NeuRX Health, Inc.[N1]

Odyssey Health has secured multi-million-dollar service contracts and financing facilities, indicating some commercial traction and investor confidence. Its focus on innovative medical devices like the Save-A-Life choking rescue device and entry into the sizable breast cancer market represent potential growth avenues. The company's strategy to license and develop products through third-party partnerships may allow efficient resource use and faster product advancement. Recent equity raises and debt conversions demonstrate ongoing capital access to support operations and development.[S1][S2]

The company faces significant financial challenges, including a net loss of $5.73 million in fiscal 2026 and a current ratio of 0.01, indicating liquidity risk. There is substantial doubt about its ability to continue as a going concern without additional financing. None of its product candidates have received FDA clearance or approval, and the company has a limited operating history with no recent revenue. Dependence on debt financing and convertible notes with Mast Hill Fund, L.P. adds financial risk. The lack of dividends and minimal physical assets further constrain financial flexibility.[S1][S2]

Odyssey Health's moat is limited due to its early-stage product development status without FDA approvals and a lack of commercialized products. Its business model relies on licensing, third-party development, and distribution, which may limit proprietary advantages. The company's recent entry into the breast cancer marketplace and development of unique medical devices could provide future differentiation if regulatory approvals and market adoption occur. However, current financial constraints and operational risks present challenges to establishing a sustainable competitive advantage.[S1]

• Liquidity and Going Concern Risk: The company has a very low current ratio of 0.01 and cash ratio of 0 as of July 31, 2026, with substantial doubt about its ability to continue as a going concern without additional financing.
• Regulatory Approval Risk: None of Odyssey Health's product candidates have received FDA clearance or approval, which is critical for commercial sales and revenue generation.
• Financial Risk: The company reported a net loss of $5.73 million for fiscal 2026 and relies heavily on debt financing and equity sales, which may dilute shareholders and increase financial obligations.
• Operational Risk: Odyssey Health has a limited operating history and no recent revenue, with ongoing development and licensing activities dependent on securing adequate funding.
• Market and Competitive Risk: The medical device and pharmaceutical markets are highly competitive and regulated, posing challenges for new entrants like Odyssey Health to establish market share.

• Odyssey Health, Inc. develops or acquires unique medical-related products, engaging third parties for development, manufacturing, and distribution.
• The company has two main technologies in research and development: CardioMap heart monitoring and screening device, and Save-A-Life choking rescue device.
• None of the product candidates have received FDA clearance or approval for commercial sale as of the latest filings.
• Odyssey Health provides maintenance and related services under a Maintenance Agreement with Mast Hill Fund, L.P., generating approximately $252,450 per year.
• The company secured a multi-million-dollar, nine-year service contract and financing facility for up to $25 million.
• Odyssey Health entered the $26 billion breast cancer marketplace as of October 2025.
• The company has been advancing development of its Save A Life choking rescue device.
• Odyssey Health closed an asset sale of its neurological drug technology pipeline including a concussion drug candidate with Oragenics, Inc.
• The company has been strengthening its balance sheet with net equity raises, including $8.7 million in net equity as of March 2024.
• Odyssey Health's stock trades on the OTC Markets under the symbol 'ODYY' with approximately 110 million shares outstanding as of October 27, 2026.
• The company reported a net loss of $5.73 million for the fiscal year ended July 31, 2026, with basic and diluted EPS of -$0.05 per share.
• Current assets were $147,859 and current liabilities were $12,277,546 as of July 31, 2026, resulting in a current ratio of 0.01 and a cash ratio of 0.
• The company has a history of financing operations primarily through debt financing and limited sales of common stock.
• Odyssey Health has convertible promissory notes with Mast Hill Fund, L.P. with recent amendments and conversions.
• The company owns no real property and leases minimal office space in Las Vegas, Nevada.
• There are no current legal proceedings involving Odyssey Health as of the latest filing.
• The Board of Directors and Corporate Governance and Nominating Committee oversee cybersecurity risks and provide annual updates to the Board.
• General and administrative expenses decreased by 10.6% in fiscal 2026 compared to fiscal 2025, primarily due to lower public company expenses and stock-based compensation.
• Interest expense increased significantly in fiscal 2026 due to higher weighted average debt outstanding.
• The company recognized a gain on extinguishment of accounts payable of $759,114 in fiscal 2026 due to vendor forgiveness.
• Odyssey Health has not paid dividends and does not provide assurance of future dividends.
• The company faces substantial doubt about its ability to continue as a going concern and may need additional financing to continue operations.
• The company has granted stock options to non-employee consultants as debt relief consideration.
• Odyssey Health's business model includes licensing and developing products upon receiving adequate funding.
• The company has engaged third-party research and development firms and applies for trademarks and patents as products advance.
• The company has a limited operating history and no revenue reported for recent years.
• Odyssey Health's recent news includes securing multi-million-dollar contracts and entering new markets such as breast cancer.
• The company has been active in investor relations and business development activities.
• Odyssey Health's financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.